Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study.
Laura E BarrettHeather L GardnerLisa G BarberAbbey SadowskiCheryl A LondonPublished in: BMC veterinary research (2019)
Oclacitinib is well tolerated when given in combination with carboplatin or doxorubicin. Future work is needed to explore whether efficacy is enhanced in this setting.